Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Nurix Therapeutics, Inc. ( NRIX ) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 3:00 PM EDT Company Participants Jason Kantor - Chief Business Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Wells Fargo Securities, LLC, Research Division All right, everyone. I think we'll get started here with our next fireside discussion. My name is Derek Archila. I'm one of the senior biotech analysts here at Wells. I'm very excited to have with us Nurix Therapeutics. From the company, we have Jason Kantor, Chief Business Officer. Jason, good to see you. Jason Kantor Chief Business Officer Good to see you, Derek. Thank you so much for having us. Question-and-Answer Session Derek Archila Wells Fargo Securities, LLC, Research Division Yes. I mean maybe just to start off, a lot of things going on at Nurix. You guys announced a big deal on Bexdeg and other things. So maybe give us kind of the state of the business first, and then we can kind of get into more specific questions. Jason Kantor Chief Business Officer Sure. Terrific. So for those who don't know Nurix well, we are a multiproduct, multi-therapeutic area, biopharma focused on targeted protein degradation. Our lead asset is a degrader of BTK, which is a central node in B-cell signaling as well as other immune cells. It's in pivotal studies for CLL and is moving into Phase II for chronic spontaneous urticaria, CSU, and also multiple sclerosis, MS. We've got partnerships with Roche, as you mentioned, for Bexdeg, but also discovery partnerships with Gilead, Sanofi and Pfizer. We've got -- our lead programs in those collaborations include a STAT6 degrader with Sanofi and an IRAK4 degrader with Gilead, and I'm very happy to be here. Thank you very much. Derek Archila